Clinical Trials Directory

A Phase II Study of Dasatinib (Sprycel®) (NSC #732517) as Primary Therapy Followed by Transplantation for Adults ? 18 Years With Newly Diagnosed PH+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOG

This phase II clinical trial studies how well dasatinib followed by stem cell transplant works in treating older patients with newly diagnosed acute lymphoblastic leukemia. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Monoclonal antibodies, such as alemtuzumab, may interfere with the ability of cancer cells to grow and spread. Giving more than one drug (combination chemotherapy) and giving dasatinib together with chemotherapy may kill more cancer cells.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • biological : alemtuzumab
  • biological : pegfilgrastim
  • biological : filgrastim
  • drug : cyclophosphamide
  • drug : cytarabine
  • drug : dasatinib
  • drug : daunorubicin hydrochloride
  • drug : Dexamethasone
  • drug : etoposide phosphate
  • drug : fludarabine phosphate
  • drug : leucovorin calcium
  • drug : melphalan
  • drug : tacrolimus
  • drug : vincristine sulfate
  • drug : methotrexate
  • drug : mercaptopurine
  • other : pharmacological study
  • other : laboratory biomarker analysis
  • procedure : in vitro-treated peripheral blood stem cell transplantation
  • procedure : autologous hematopoietic stem cell transplantation
  • procedure : allogeneic hematopoietic stem cell transplantation

Phase: Phase 2


Ages Eligible For Study:

18 Years - N/A

External Links

Explore related trials

Contact information

Primary Contact:

Joselene Sipin-Sayno 6507368113

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: